二次肿瘤细胞减灭术治疗复发性卵巢癌的研究进展

二次肿瘤细胞减灭术（secondary cytoreductive surgery，SCS）作为复发性卵巢癌的治疗方法之一，以完全切除肿瘤，使残留病灶达到最小为目标，主要适用于铂敏感性复发性上皮性卵巢癌(epithelial ovarian cancer,EOC)的治疗。这种再次手术切除肿瘤病灶的方式与传统治疗方式相比，能否改善复发性卵巢癌患者生存和预后，给患者带来新的希望，目前没有确切结论。术前准确预测SCS的效果，选择更适合进行SCS的复发性卵巢癌患者，分析影响SCS预后的因素，可以使SCS更好地应用于复发性卵巢癌的治疗。本文对SCS治疗复发性卵巢癌的适应证、手术方法以及预后影响因素进行综述。

Research progress of the secondary cytoreductive surgery in the treatment of recurrent ovarian cancer

Secondary of cytoreductive surgery(SCS)is one of the treatment methods for recurrent ovarian cancer.The goal is to completely remove the tumor and minimize the residual lesions.It is mainly used for the treatment of platinum-sensitive recurrent epithelial ovarian cancer(EOC).Compared with the traditional chemotherapy method of chemotherapy,this method of resecting tumor lesions can improve the survival and prognosis of patients with recurrent ovarian cancer and bring new hope for patients with recurrent ovarian cancer.There is no definite conclusion yet.Precise prediction of the effects of SCS,selection of patients more suitable for SCS,and analysis of factors affecting the prognosis of SCS patients will greatly improve the survival of SCS patients and make SCS better applied to the treatment of recurrent ovarian cancer.This article reviews the safety and feasibility of SCS,surgical methods,and factors affecting the prognosis of SCS.